SEC 13F Intelligence

Decheng Capital Management III (Cayman), LLC / ZNTL

Decheng Capital Management III (Cayman), LLC’s Zentalis Pharmaceuticals Inc Position

Does Decheng Capital Management III (Cayman), LLC own Zentalis Pharmaceuticals Inc (ZNTL)? Yes — 2.10M shares worth $42M (+14.06% of its 13F portfolio) as of Q4 2023.

Position Value
$42M
Q4 2023
Shares
2.10M
% of Portfolio
+14.06%
Quarters Held
7
currently held

Position History ZNTL

Reported value by quarter
Q2 ’22: $51MQ2 ’22Q3 ’22: $40MQ3 ’22Q4 ’22: $37MQ4 ’22Q1 ’23: $31MQ1 ’23Q2 ’23: $59MQ2 ’23Q3 ’23: $42MQ3 ’23Q4 ’23: $42MQ4 ’23filingsflow.com
QuarterSharesValue% of Portfolio
Q4 20232.10M$42M+14.06%
Q3 20232.10M$42M+13.46%
Q2 20232.10M$59M+18.58%
Q1 20231.82M$31M+12.66%
Q4 20221.82M$37M+13.75%
Q3 20221.82M$40M+14.33%
Q2 20221.82M$51M+19.44%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Decheng Capital Management III (Cayman), LLC’s full portfolio or all institutional holders of ZNTL.